First Line Treatment Trial in Multiple Myeloma, Finnish Myeloma Group- Multiple Myeloma 02 (FMG-MM02)
A Prospective Phase II Study to Assess Immunophenotypic Remission After 3-drug Induction Followed by Randomized Stem Cell Mobilization, Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma
Sponsor: Celgene Corporation
A PHASE2 clinical study on Multiple Myeloma, this trial is completed. The trial is conducted by Celgene Corporation and has accumulated 8 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
May 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Apr 2019 — May 2020 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 3 earlier versions
-
Mar 2019 — Apr 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Mar 2019 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
First recorded
Jan 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Celgene Corporation
- Helsinki University Central Hospital
- Jyväskylä Central Hospital
- Kainuu Central Hospital, Kajaani
- Kanta-Häme Central Hospital
- Kuopio University Hospital
- Kymenlaakso Central Hospital Kotka Finland
- Mikkeli Central Hospital
- Oulu University Hospital
- Satakunta Central Hospital
- Tampere University Hospital
- Turku University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Helsinki, Finland , Hämeenlinna, Finland , Jyväskylä, Finland , Kajaani, Finland , Kemi, Finland , Kotka, Finland , Kuopio, Finland , Mikkeli, Finland , Oulu, Finland , Pori, Finland and 2 more locations